The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease

References

• Vatn MH. Natural history and complications of IBD. Curr Gastroenterol Rep. 2009;11:481–487.
   PubMedGoogle Scholar
• Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–1201.
   PubMed Web of Science ®Google Scholar
• Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–422.
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463–468.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Reinisch W, Colombel J, etet al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut. 2014;63:88–95.
   PubMed Web of Science ®Google Scholar
• Mooiweer E, Severs M, Shipper M, et al. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2015;9:50–55.
   PubMed Web of Science ®Google Scholar
• Danik JS, Chasman DI, Cannon CP, et al. Influence of genetic variation in the c-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet. 2006;70:705–716.
   PubMed Web of Science ®Google Scholar
• Henderson P, Kennedy NA, Van Limbergen JE, et al. Serum c-reactive protein and crp genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy. Inflamm Bowel Dis. 2015;21:596–605.
   PubMed Web of Science ®Google Scholar
• van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.
   PubMed Web of Science ®Google Scholar
• Røseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793–798.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Kolho KL, et al. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40–46.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332–341.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Karkkainen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-tnf-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008;14:1392–1398.
   PubMed Web of Science ®Google Scholar
• Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and pmn-elastase, crp, and clinical indices. Am J Gastroenterol. 2008;103:162–169.
   PubMed Web of Science ®Google Scholar
• Manz M, Burri E, Rothen C, et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol. 2012;12:5.
   PubMed Web of Science ®Google Scholar
• Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22:340–345.
   PubMed Web of Science ®Google Scholar
• Mosli M, Zou G, Garg S, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:802–819.
   PubMed Web of Science ®Google Scholar
• Kwapisz L, Mosli M, Chande N, et al. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: a diagnostic cohort study. Saudi J Gastroenterol. 2015;21:360–366.
   PubMed Web of Science ®Google Scholar
• Sydora MJ, Sydora BC, Fedorak RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis. 2012;6:207–214.
   PubMed Web of Science ®Google Scholar
• Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47:506–513.
   PubMed Web of Science ®Google Scholar
• Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013;17.
   Web of Science ®Google Scholar
• Costa F, Mumolo M, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364–368.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterol. 2000;119:15–22.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45:872–877.
   PubMed Web of Science ®Google Scholar
• Alper A, Zhange L, Pashankar DS. Correlation of erythrocyte sedimentation rate and c-reactive protein with pediatric inflammatory bowel disease activity. J Pediatr Gastroenterol Nutr. 2016. [Epub ahead of print].
   Web of Science ®Google Scholar
• Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:74–80.
   PubMed Web of Science ®Google Scholar
• De Vos M, Louis EJ, Jahnsen JJ, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111–2117.
   PubMed Web of Science ®Google Scholar
• Lobatón T, López-García A, Rodríguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis. 2013;7:e641–e651.
   PubMedGoogle Scholar
• Moron JMV, Manrique HP, Machancoses FH, et al. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin. Rev Esp Enferm Dig. 2017;109:130–136.
   PubMed Web of Science ®Google Scholar
• Molander P, af Björkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18:2011–2017.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Rosenfeld G, Bressler B, et al. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:742–756.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang Z, Shi H, et al. Faecal calprotectin concentrations in gastrointestinal diseases. J Int Med Res. 2013;41:1357–1361.
   PubMed Web of Science ®Google Scholar
• Licata A, Randazzo C, Cappello M, et al. Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea. J Clin Gastroenterol. 2012;46:504–508.
   PubMed Web of Science ®Google Scholar
• Pavlisis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scand J Gastroenterol. 2013;48:1048–1054.
   PubMed Web of Science ®Google Scholar
• Rogler G, Aldeguer X, Kruis W, et al. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: Expert clinical opinion. J Crohns Colitis. 2013;7:670–677.
   PubMed Web of Science ®Google Scholar
• Shastri YM, Bergis D, Povse N, et al. Prospective Multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med. 2008;121:1099–1106.
   PubMed Web of Science ®Google Scholar